
Vorasidenib analyses featured at SNO 2026 examine longer-term outcomes and seizure burden in IDH-mutant glioma, underscoring the importance of sustained monitoring during oral therapy.
Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses the rate of treatment-related mortality and the most common causes in the treatment of Burkitt lymphoma.
Pharmacy Times interviewed Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, to discuss his SOHO 2021 conference presentation on prognostication and treatment of Burkitt lymphoma in the modern era.
During the interview, Olszewski discussed the rate of treatment-related mortality and the most common causes in the treatment of Burkitt lymphoma.




